As competitive HMG-CoA reductase (HMGCR) inhibitors, statins not only reduce cholesterol
and improve cardiovascular risk, but also exhibit pleiotropic effects that are independent of …

Simple Summary The current meta-analysis highlighted that proton pump inhibitors (PPIs)
and histamine-2-receptor antagonists (H2RAs) could impact immune checkpoint inhibitors …

Ample evidence indicates that the gut microbiome is a tumor-extrinsic factor associated with
antitumor response to anti-programmed cell death protein-1 (PD-1) therapy, but …

The cancer–immune dialogue subject to immuno-oncological intervention is profoundly
influenced by microenvironmental factors. Indeed, the mucosal microbiota—and more …

Immune checkpoint blockade (ICB) therapy has achieved breakthroughs in the treatment of
advanced non–small cell lung cancer (NSCLC). Nevertheless, the low response due to …

Background Some concomitant medications including antibiotics (ATB) have been
reproducibly associated with worse survival following immune checkpoint inhibitors (ICIs) in …

Background Concomitant medications are known to impact on clinical outcomes of patients
treated with immune checkpoint inhibitors (ICIs). We aimed weighing the role of different …

Highlights•Co-medications must be carefully assessed at checkpoint inhibitors
initiation.•Withdrawal of proton pump inhibitors and psychotropic drugs should be …

The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, also known
as statins, are administered as first-line therapy for hypercholesterolemia, both as primary …

Background Anti-PD-1 immune checkpoint blockade is approved for first-line treatment of
recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), but few patients …